Effect of Escitalopram on Mental Stress–Induced Myocardial Ischemia: Results of the REMIT Trial | Cardiology | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.236.187.155. Please contact the publisher to request reinstatement.
1.
Dimsdale JE. Psychological stress and cardiovascular disease.  J Am Coll Cardiol. 2008;51(13):1237-124618371552PubMedGoogle ScholarCrossref
2.
Trichopoulos D, Katsouyanni K, Zavitsanos X, Tzonou A, Dalla-Vorgia P. Psychological stress and fatal heart attack: the Athens (1981) earthquake natural experiment.  Lancet. 1983;1(8322):441-4446131167PubMedGoogle ScholarCrossref
3.
Jiao Z, Kakoulides SV, Moscona J,  et al.  Effect of Hurricane Katrina on incidence of acute myocardial infarction in New Orleans three years after the storm.  Am J Cardiol. 2012;109(4):502-50522154089PubMedGoogle ScholarCrossref
4.
Aoki T, Fukumoto Y, Yasuda S,  et al.  The Great East Japan Earthquake Disaster and cardiovascular diseases.  Eur Heart J. 2012;33(22):2796-280322930461PubMedGoogle ScholarCrossref
5.
Strike PC, Steptoe A. Systematic review of mental stress–induced myocardial ischaemia.  Eur Heart J. 2003;24(8):690-70312713764PubMedGoogle ScholarCrossref
6.
Jiang W, Babyak M, Krantz DS,  et al.  Mental stress–induced myocardial ischemia and cardiac events.  JAMA. 1996;275(21):1651-16568637138PubMedGoogle ScholarCrossref
7.
Bairey CN, Krantz DS, DeQuattro V, Berman DS, Rozanski A. Effect of beta-blockade on low heart rate-related ischemia during mental stress.  J Am Coll Cardiol. 1991;17(6):1388-13951673134PubMedGoogle ScholarCrossref
8.
Andrews TC, Parker JD, Jacobs S,  et al.  Effects of therapy with nifedipine GITS or atenolol on mental stress−induced ischemic left ventricular dysfunction.  J Am Coll Cardiol. 1998;32(6):1680-16869822096PubMedGoogle ScholarCrossref
9.
Blumenthal JA, Sherwood A, Babyak MA,  et al.  Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial.  JAMA. 2005;293(13):1626-163415811982PubMedGoogle ScholarCrossref
10.
Golding M, Kotlyar M, Carson SW,  et al.  Effects of paroxetine on cardiovascular response to mental stress in subjects with a history of coronary artery disease and no psychiatric diagnoses.  Psychopharmacology (Berl). 2005;182(3):321-32616001113PubMedGoogle ScholarCrossref
11.
Kamarck TW, Muldoon MF, Manuck SB,  et al.  Citalopram improves metabolic risk factors among high hostile adults: results of a placebo-controlled intervention.  Psychoneuroendocrinology. 2011;36(7):1070-107921306829PubMedGoogle ScholarCrossref
12.
Camacho A, Dimsdale JE. Platelets and psychiatry: lessons learned from old and new studies.  Psychosom Med. 2000;62(3):326-33610845346PubMedGoogle Scholar
13.
Brydon L, Magid K, Steptoe A. Platelets, coronary heart disease, and stress.  Brain Behav Immun. 2006;20(2):113-11916183245PubMedGoogle ScholarCrossref
14.
Jiang W, Velazquez EJ, Samad Z,  et al.  Responses of mental stress–induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial.  Am Heart J. 2012;163(1):20-2622172432PubMedGoogle ScholarCrossref
15.
Douglas PS, DeCara JM, Devereux RB,  et al; American Society of Echocardiography Standards; American College of Cardiology Foundation.  Echocardiographic imaging in clinical trials: American Society of Echocardiography Standards for echocardiography core laboratories: endorsed by the American College of Cardiology Foundation.  J Am Soc Echocardiogr. 2009;22(7):755-76519560654PubMedGoogle ScholarCrossref
16.
Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory II. San Antonio, TX: Psychological Corporation; 1996
17.
Spielberger CD, Gorssuch RL, Jacobs GA. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press Inc; 1983
18.
Cook WW, Medley DM. Proposed hostility and pharisaic-virtue scales for the MMPI.  J Appl Psychol. 1954;38:414-418Google ScholarCrossref
19.
Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress.  J Health Soc Behav. 1983;24(4):385-3966668417PubMedGoogle ScholarCrossref
20.
Akinboboye O, Krantz DS, Kop WJ,  et al.  Comparison of mental stress–induced myocardial ischemia in coronary artery disease patients with versus without left ventricular dysfunction.  Am J Cardiol. 2005;95(3):322-32615670538PubMedGoogle ScholarCrossref
21.
Jiang W, Samad Z, Boyle S,  et al.  Prevalence and clinical characteristics of mental stress–induced myocardial ischemia in patients with coronary heart disease.  J Am Coll Cardiol. 2013;61(7):714-72223410543PubMedGoogle ScholarCrossref
22.
Schafer JL. Multiple imputation: a primer.  Stat Methods Med Res. 1999;8(1):3-1510347857PubMedGoogle ScholarCrossref
23.
Rozanski A, Bairey CN, Krantz DS,  et al.  Mental stress and the induction of silent myocardial ischemia in patients with coronary artery disease.  N Engl J Med. 1988;318(16):1005-10123352695PubMedGoogle ScholarCrossref
24.
Jain D, Burg M, Soufer R, Zaret BL. Prognostic implications of mental stress–induced silent left ventricular dysfunction in patients with stable angina pectoris.  Am J Cardiol. 1995;76(1):31-357793399PubMedGoogle ScholarCrossref
25.
Glassman AH, O’Connor CM, Califf RM,  et al; Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group.  Sertraline treatment of major depression in patients with acute MI or unstable angina.  JAMA. 2002;288(6):701-70912169073PubMedGoogle ScholarCrossref
26.
O’Connor CM, Jiang W, Kuchibhatla M,  et al; SADHART-CHF Investigators.  Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial.  J Am Coll Cardiol. 2010;56(9):692-69920723799PubMedGoogle ScholarCrossref
27.
Taylor CB, Youngblood ME, Catellier D,  et al;  ENRICHD Investigators.  Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction.  Arch Gen Psychiatry. 2005;62(7):792-79815997021PubMedGoogle ScholarCrossref
28.
Breum L, Bjerre U, Bak JF, Jacobsen S, Astrup A. Long-term effects of fluoxetine on glycemic control in obese patients with non–insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity.  Metabolism. 1995;44(12):1570-15768786726PubMedGoogle ScholarCrossref
29.
Daubresse JC, Kolanowski J, Krzentowski G, Kutnowski M, Scheen A, Van Gaal L. Usefulness of fluoxetine in obese non–insulin-dependent diabetics: a multicenter study.  Obes Res. 1996;4(4):391-3968822764PubMedGoogle ScholarCrossref
30.
Gray DS, Fujioka K, Devine W, Bray GA. Fluoxetine treatment of the obese diabetic.  Int J Obes Relat Metab Disord. 1992;16(3):193-1981317828PubMedGoogle Scholar
31.
Maheux P, Ducros F, Bourque J, Garon J, Chiasson JL. Fluoxetine improves insulin sensitivity in obese patients with non–insulin-dependent diabetes mellitus independently of weight loss.  Int J Obes Relat Metab Disord. 1997;21(2):97-102Google ScholarCrossref
32.
O’Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients.  Diabet Med. 1994;11(1):105-1108181239PubMedGoogle ScholarCrossref
33.
Potter van Loon BJ, Radder JK, Frölich M, Krans HMJ, Zwinderman AH, Meinders AE. Fluoxetine increases insulin action in obese nondiabetic and in obese non–insulin-dependent diabetic individuals.  Int J Obes Relat Metab Disord. 1992;16(2):79-851316330PubMedGoogle Scholar
34.
Kamarck TW, Haskett RF, Muldoon M,  et al.  Citalopram intervention for hostility: results of a randomized clinical trial.  J Consult Clin Psychol. 2009;77(1):174-18819170463PubMedGoogle ScholarCrossref
35.
Barefoot JC, Brummett BH, Williams RB,  et al.  Recovery expectations and long-term prognosis of patients with coronary heart disease.  Arch Intern Med. 2011;171(10):929-93521357800PubMedGoogle ScholarCrossref
36.
McGregor M. Mechanisms of transient myocardial ischemia.  Can J Cardiol. 1986;suppl A:53A-58A3756598PubMedGoogle Scholar
37.
McCloskey DJ, Postolache TT, Vittone BJ,  et al.  Selective serotonin reuptake inhibitors: measurement of effect on platelet function.  Transl Res. 2008;151(3):168-17218279816PubMedGoogle ScholarCrossref
38.
Przyklenk K, Frelinger AL III, Linden MD,  et al.  Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis.  J Thromb Haemost. 2010;8(2):331-34019922435PubMedGoogle ScholarCrossref
Preliminary Communication
May 22, 2013

Effect of Escitalopram on Mental Stress–Induced Myocardial Ischemia: Results of the REMIT Trial

Author Affiliations

Author Affiliations: Departments of Medicine (Drs Jiang, Velazquez, Samad, Becker, Ortel, Rogers, and O’Connor) and Psychiatry and Behavioral Sciences (Drs Jiang, Boyle, Kuhn, and Williams), Center for Aging (Dr Kuchibhatla), and Duke Heart Mind Center (Drs Jiang, Boyle, and O’Connor), Duke University Medical Center; and Duke Clinical Research Institute (Drs Jiang, Velazquez, Becker, Rogers, and O’Connor), Durham, North Carolina.

JAMA. 2013;309(20):2139-2149. doi:10.1001/jama.2013.5566
Abstract

Importance Mental stress can induce myocardial ischemia and also has been implicated in triggering cardiac events. However, pharmacological interventions aimed at reducing mental stress–induced myocardial ischemia (MSIMI) have not been well studied.

Objective To examine the effects of 6 weeks of escitalopram treatment vs placebo on MSIMI and other psychological stress–related biophysiological and emotional parameters.

Design, Setting, and Participants The REMIT (Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment) study, a randomized, double-blind, placebo-controlled trial of patients with clinically stable coronary heart disease and laboratory-diagnosed MSIMI. Enrollment occurred from July 24, 2007, through August 24, 2011, at a tertiary medical center.

Interventions Eligible participants were randomized 1:1 to receive escitalopram (dose began at 5 mg/d, with titration to 20 mg/d in 3 weeks) or placebo over 6 weeks.

Main Outcomes and Measures Occurrence of MSIMI, defined as development or worsening of regional wall motion abnormality; left ventricular ejection fraction reduction of 8% or more; and/or horizontal or down-sloping ST-segment depression of 1 mm or more in 2 or more leads, lasting for 3 or more consecutive beats, during 1 or more of 3 mental stressor tasks.

Results Of 127 participants randomized to receive escitalopram (n = 64) or placebo (n = 63), 112 (88.2%) completed end point assessments (n = 56 in each group). At the end of 6 weeks, more patients taking escitalopram (34.2% [95% CI, 25.4%-43.0%]) had absence of MSIMI during the 3 mental stressor tasks compared with patients taking placebo (17.5% [95% CI, 10.4%-24.5%]), based on the unadjusted multiple imputation model for intention-to-treat analysis. A significant difference favoring escitalopram was observed (odds ratio, 2.62 [95% CI, 1.06-6.44]). Rates of exercise-induced ischemia were slightly lower at 6 weeks in the escitalopram group (45.8% [95% CI, 36.6%-55.0%]) than in patients receiving placebo (52.5% [95% CI, 43.3%-61.8%]), but this difference was not statistically significant (adjusted odds ratio; 1.24 [95% CI, 0.60-2.58]; P = .56).

Conclusions and Relevance Among patients with stable coronary heart disease and baseline MSIMI, 6 weeks of escitalopram, compared with placebo, resulted in a lower rate of MSIMI. There was no statistically significant difference in exercise-induced ischemia. Replication of these results in multicenter settings and investigations of other medications for reducing MSIMI are needed.

Trial Registration clinicaltrials.gov Identifier: NCT00574847 .

×